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Abstract
Background: Drug resistance remains a great challenge in the treatment of pancreatic cancer. The goal of this
study was to determine whether TGF-b1 is associated with drug resistance in pancreatic cancer.
Methods: Pancreatic cancer BxPC3 cells were stably transfected with TGF-b1 cDNA. Cellular morphology and cell
cycle were determined and the suppressive subtracted hybridization (SSH) assay was performed to identify
differentially expressed genes induced by TGF-b1. Western blotting and immunohistochemistry were used to
detect expression of TGF-b1-related genes in the cells and tissue samples. After that, the cells were further treated
with an anti-cancer drug (e.g., cisplatin) after pre-incubated with the recombinant TGF-b1 plus PKCa inhibitor
Gö6976. TGF-b1 type II receptor, TbRII was also knocked down using TbRII siRNA to assess the effects of these
drugs in the cells. Cell viability was assessed by MTT assay.
Results: Overexpression of TGF-b1 leads to a markedly increased invasion potential but a reduced growth rate in
BxPC3 cells. Recombinant TGF-b1 protein increases expression of PKCa in BxPC3 cells, a result that we confirmed
by SSH. Moreover, TGF-b1 reduced the sensitivity of BxPC3 cells to cisplatin treatment, and this was mediated by
upregulation of PKCa. However, blockage of PKCa with Gö6976 and TbRII with siRNA reversed the resistance of
BxPC3 cells to gemcitabine, even in the presence of TGF-b1. Immunohistochemical data show that pancreatic
cancers overexpress TGF-b1 and P-gp relative to normal tissues. In addition, TGF-b1 expression is associated with
P-gp and membranous PKCa expression in pancreatic cancer.
Conclusions: TGF-b1-induced drug resistance in pancreatic cancer cells was associated with PKCa expression. The
PKCa inhibitor Gö6976 could be a promising agent to sensitize pancreatic cancer cells to chemotherapy.
Background
Drug resistance poses a significant challenge to achiev-
ing clinical control of pancreatic cancer. Resistance to
chemotherapy frequently results in disease relapse and
tumor recurrence, leading to shorter survival times for
patients with pancreatic cancer than those with other
gastrointestinal cancers. Elimination or minimization of
drug resistance will improve our ability to control pan-
creatic cancer and increase patient survival. However,
there are multiple etiologies for drug resistance, and
they are not well understood.
PKCa is a classic member of the protein kinase C
family, and some studies have demonstrated an associa-
tion between PKCa and drug resistance in human can-
cers [1,2]. PKCa-associated drug resistance is likely
mediated by P-gp, which is encoded by the multidrug
resistant gene 1 (MDR1)g e n e .P - g pb e l o n g st ot h e
ATP-binding cassette (ABC) transporter superfamily,
and it functions as a drug efflux pump in multidrug
resistance. PKCa modulates the function of P-gp via
phosphorylation of the P-gp intracellular domain or
activation of the MDR1 gene promoter. Curcumin [3],
hammerhead ribozymes [4], and antisense oligonucleo-
tides [5], which all target P-gp, have been shown to
improve the efficacy of chemotherapy in a variety of
cancer models. However, the molecular mechanism of
* Correspondence: mhzhu2000@hotmail.com
† Contributed equally
1Department of Pathology, Changhai Hospital, Second Military Medical
University, Shanghai, 200433, China
Full list of author information is available at the end of the article
Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:104
http://www.jeccr.com/content/29/1/104
© 2010 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.PKCa/P-gp-initiated drug resistance in pancreatic can-
cer is poorly understood.
There are three subtypes of transforming growth fac-
tor-b in humans: TGF-b1, TGF-b2, and TGF-b3. This
growth factor is upregulated in some human cancers,
and the various subtypes play crucial roles in tissue
regeneration, cell differentiation, embryonic develop-
ment, and regulation of the immune system. TGF-b1
is a multifunctional cytokine endowed with both anti-
neoplastic and pro-oncogenic activities in human can-
cers. TGF-b1 has been shown to enhance the efficacy of
anti-cancer drugs by repressing cellular proliferation
[6-10]. Smad4 mediates the anti-neoplastic activities of
TGF-b1 (such as inhibition of tumor cell growth and
induction of apoptosis [11-14]. For example, TGF-b1
induces the antitumor activity of dihydrotestosterone
(DTH) in prostate cancer by causing the tumor cells to
undergo apoptosis. This effect is mediated through
Smad4, which negatively regulates the growth of epithe-
lial cells and the extracellular matrix (ECM) [15].
SMAD4 is mutated in many cancers, including pan-
creatic cancer. It is a tumor suppressor gene that regu-
lates the TGF-b signal transduction pathway. Indeed,
several studies have demonstrated that TGF-b1p r o -
motes invasiveness and metastasis if Smad4 is absent or
mutated via a Smad4-independent pathway [16-19]. To
date, no one has reported a correlation between TGF-b1
and chemotherapy resistance in pancreatic cancer.
The information presented above suggests that
Smad4-dependent and -independent signaling pathways
regulate cancer cell resistance to chemotherapy. This is
particularly important in pancreatic cancer chemother-
apy because more than 50% of pancreatic cancers have
inactivated Smad4 protein [20], which may result in
activation of the Smad4-independent TGF-b1 pathway
when patients undergo such treatment. In this study, we
determined whether TGF-b1 is associated with drug
resistance in pancreatic cancer and then explored the
possible underlying mechanism. TGF-b1 induces drug
resistance in a Smad4-null pancreatic cancer cell line.
The effect of TGF-b1 was mediated by PKCa/P-gp and
the epithelial-to-mesenchymal transition (EMT). More-
over, a selective inhibitor of PKCa,G ő6976, was able to
reverse the effects of TGF-b1-induced drug resistance in
pancreatic cancer cells.
Materials and methods
Cell line and tissue samples
The human pancreatic cancer cell line BxPC3, which
shows homogeneous loss of SMAD4, was generously
provided by Dr. Zhao-shen Li of the Department of
Gastroenterology, Changhai Hospital, Shanghai. The
cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) plus 10% fetal bovine serum, 100 U/ml of
penicillin and streptomycin (all were from Invitrogen-
Gibco, Carlsbad, CA, USA) at 37°C in a humidified
atmosphere of 95% air and 5% CO2. Tissue specimens
from 42 pancreatic ductal adenocarcinoma patients were
obtained from the Department of Pathology at Changhai
Hospital, which is affiliated with the Second Military
Medical University, Shanghai, China. Our institutional
review board approved the use of tissue samples, and
the patients all provided informed consent.
Reagents
Human recombinant TGF-b1 was purchased from
Peprotech (Rocky Hill, NJ, USA) and dissolved in phos-
phate-buffered saline (PBS) (pH 7.2) with 1 mg/ml
bovine serum albumin (BSA, from Amresco, USA).
Gö6976, a selective inhibitor of PKCa,w a sp u r c h a s e d
from Biosource (San Jose, CA, USA) and used at con-
centrations of 100 nM, 1 M and 10 M. Anti-cancer
drugs (5-FU, gemcitabine, oxaliplatin, cisplatin, CPT-11
and epirubicin) were obtained from the Department of
Oncology of Changzheng Hospital, Shanghai, China.
Gene transfection, cellular morphological changes and
mobility assay
A pcDNA3 vector containing full-length cDNA for
TGF-b1 was obtained from the Department of Pathol-
ogy, Fudan University, China. BxPC3 cells were trans-
fected with the pcDNA3/TGF-b1 plasmid or pcDNA3
as a mock control using the Lipofectamine™ 2000 trans-
fection kit (Invitrogen). The cells were then fed
with fresh selective medium containing 800 μg/ML
G418 (Invitrogen-Gibco) for 2-3 weeks, and stable gene-
transfected cell clones were individually transferred into
six-well plates for expansion to establish sublines that
stably expressed the gene product. TGF-b1 expression
was confirmed by Western blot analysis. Cellular mor-
phology was observed using an inverted phase contrast
microscope (x40) and photographed with a digital cam-
era (Olympus, Japan).
For the wound healing assay, cells were plated in 24-
well cell culture plates. After they reached confluence, a
plastic pipette tip was drawn across the center of the
plates to produce a clean 1 millimeter-wide wound area.
Cell migration into the wound area was examined
24 hours after culturing in DMEM with 10% FBS.
Protein extraction and western blotting
Cells were grown in DMEM for 3 days, and total cellular
proteins were isolated using a cell lysis buffer containing
phosphatase inhibitor (Merck, Germany). The protein
concentration was then measured with a BioRad Protein
Assay Kit II (BioRad Laboratories, Hercules, CA) accord-
ing to the manufacturer’s protocol. Samples containing
50 μg of protein from the cells were separated by 10-14%
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trophoretically to a Hybond-C nitrocellulose membrane
(GE Healthcare, Arlington Heights, IL) at 500 mA for 2
h at 4°C. The membrane was subsequently stained with
0.5% Ponceau S containing 1% acetic acid to confirm that
the proteins were loaded equally and to verify transfer
efficiency. The membranes were next incubated overnight
in a blocking solution containing 5% bovine skim milk
and 0.1% Tween 20 in PBS at 4°C. The next day, the
membranes were incubated with primary antibodies for 2
h at room temperature. The antibodies used were anti-
TGF-b1 polyclonal antibody (sc-146), anti-p21
WAF1
monoclonal antibody (sc-817), anti-cyclinD1 polyclonal
antibody (sc-20044), anti-SMA monoclonal antibody (sc-
56499), anti-GAPDH polyclonal antibody (sc-20357) (all
from Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), anti-p38 polyclonal antibody (B205405) (Stressgen,
Ann Arbor, MI, USA), anti-p-p38 polyclonal antibody
(AF1576), anti-ERK1/2 polyclonal antibody (AF1576),
anti-pERK1/2 polyclonal antibody (AF1018) (R&D Sys-
tems, Minneapolis, MN, USA), anti-P-gp (MS-660) (Lab
Vision, Fremont, CA, USA,) anti-TbRII polyclonal anti-
body (cst-2518) and anti-PKCa polyclonal antibody (cst-
2056) (Cell Signal Technology, Beverly, MA, USA). The
membranes were washed in PBS and incubated for 1.5 h
with a chemiluminescent system for HRP-conjugated
antibodies (Santa Cruz Biotechnology) to visualize the
protein bands on X-ray film.
Immunohistochemical analysis
Tissue sections (4-μm) were cut from paraffin blocks and
deparaffinized by routine procedures. Immunohistochem-
ical analyses were performed by using the DAKO system
(DOKO, Carpinteria, CA, USA), and DAB was used as the
chromogen. The tissue sections were counterstained with
hematoxylin. The primary antibodies used included mono-
clonal anti-PKCa antibody (sc-8393), polyclonal anti-
TGF-b1 antibody (sc-146) (Santa Cruz Biotechnology,
Inc.) and monoclonal anti-P-gp antibody (M-660-P, from
Labvision). The stained sections were reviewed and scored
using an Olympus microscope. The sections were then
scored as positive or negative according to their staining
intensity and percentage of the staining.
Suppressive subtracted hybridization (SSH) screening
We performed SSH to identify changes in gene expres-
sion between stably TGFb1- and vector-only-transfected
BxPC3 cells. Total RNA was isolated from these sub-
lines by using an RNAeasy Mini kit (Qiagen, Santa
Clara, CA). Next, total RNA was reversely transcribed
into cDNA using a cDNA subtraction kit (Clontech,
Mountain View, CA, USA). An excess of driver double-
stranded cDNAs, synthesized from poly(A)+RNA, was
added to microtubes containing adaptor 1- and adaptor
2-ligand tester cDNA for the first hybridization. After
two rounds of hybridization, subtracted or differentially
expressed cDNAs were amplified by nested PCR. Pro-
ducts from the secondary PCRs were inserted into the
pUCm-T/A cloning vector, and the plasmids were then
transformed into the Escherichia coli JM109 strain for
further screening and identification. The transformants
containing subtracted cDNAs were grown on LB agar
plates containing 100 μg/ml ampicillin and X-gal (50 μl
of a 2 mg/ml stock solution per 100 mm plate), and
individual colonies were selected and grown in LB broth
at 37°C overnight for identification of differentially
expressed genes.
Dot blotting and DNA sequencing
Reverse Northern blot combined with dot blotting was
used to confirm differential expression in the subtracted
gene clones. Dots with a higher intensity in the trans-
fected group than those in the mock group were cate-
gorized as the upregulation group, and clones with
weaker signals were categorized as the downregulation
group. All clones with differentially expressed genes
were sequenced using a M13 (+) and/or M13 (-) promo-
ter flanking the cloning sites. They were then analyzed
with an Applied Biosystems 320 genetic analyzer.
Homological searches for gene identification were per-
formed with the online BLASTn and BLASTx programs.
Cell viability MTT assay
The tetrazolium dye [3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, MTT; Sigma-Aldrich, St.
Louis, MO, USA] assay was performed to assess cyto-
toxicity of different chemotherapeutic drugs to the pan-
creatic cancer cells. Briefly, ten thousand cells were
cultivated in 96-well plates with DMEM containing 1%
F B Sa n d5o r1 0n g / m lr e c o m b i n a n tT G F - b1( P e p r o -
tech). The controls contained 1% BSA only instead of
TGF-b1. To test the effect of Gö6976 in the cancer cells
treated with different chemotherapeutic drugs, a range
of concentrations of Gö6976 (100 nM, 1 μM, or 10 μM)
was added into the culture media together with 5 μg/ml
of TGF-b1. After 24 hours, the cells were treated with
anti-cancer drugs for an additional 24 hours. Following
this incubation, the culture medium was replaced with
100 μl of 0.05% MTT solution, and the cell culture was
incubated for 4 hours. The absorption rate was then
measured at 490 nm using a microplate reader (Anthos
Labtec Instruments, Austria), and the IC50 was calcu-
lated as the drug concentration that reduced the optical
density by 50%.
Construction of siRNA vector
The pSliencer2.1/U6 vector was purchased from
Ambion Company (Austin, TX, USA) to harbor siRNA.
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targeting siRNA, and the sequences were 5′-GATCCG-
TATAACACCAGCAATCCTGTTCAAGAGACAGG
ATTGCTGGTGTTATATTTTTTGGAAA-3′ (sense
sequence) and 5′-AGCTTTTCCAAAAAATATAACAC-
CAGCAATCCTGTCTCTTGAACAG-
GATTGCTGGTGTTATACG-3′ (antisense sequence).
The DNA oligonucleotides were then synthesized by
Invitrogen (Shanghai, China). Next, the sense and anti-
sense DNA oligonucleotides were annealed to form dou-
ble-stranded DNA, which was inserted into the
pSliencer2.1/U6 vector. After the sequences were con-
firmed and the vector was amplified, this vector was
transfected into the pancreatic cancer cell line. After
selection with 800 μg/mL of G418 for over three weeks,
the sublines were isolated and tested for gene silencing.
Once silencing was verified, we used these cells for drug
cytotoxicity assays.
Statistical analyses
Statistical analyses were performed with SPSS 10.0 soft-
ware. The c
2 test was used to assess immunohistochem-
ical data, and we used an ANOVA-test for the MTT
assay. All statistical tests were two-sided, and p <0 . 0 5
was considered to be statistically significant.
Results
Role of TGF-b1 in pancreatic cancer BxPC3 cells
We stably transfected a TGF-b1 expression vector into
BXPC3 cells and then assessed the alterations in pheno-
type. For example, we first determined the morphologi-
cal modifications in stably TGF-b1-transfected BxPC3
cells by comparing them to vector-control-transfected
sublines. After TGF-b1 transfection, tumor cells under-
went obvious morphological changes. In particular, the
original oval shape and tightly arranged colonies chan-
ged to spindle cells with a stellate shape and less cell-to-
cell contact (Figure 1). The wound healing assay shows
that BxPC3/TGF-b1 cells recovered from the wound
much faster than controls or the parental cell line (Fig-
ure 2). Cell cycle analysis by flow cytometry showed a
shortened S phase in BxPC3/TGF-b1c e l l s( 1 7 . 0 1±
2.65%) compared to parental cells (27.53 ± 2.42%) and
cells in the vector-only controls (26.32 ± 1.36%). At the
molecular level, expression of a-SMA, a marker of
EMT, and p21
WAF1, an inhibitor of cyclin-dependent
kinases, were significantly upregulated, while that of
cyclinD1 was reduced in stably TGF-b1-transfected
BxPC3 cells (Figure 3).
TGF-b1 reduced the sensitivity of BxPC3 cells to cisplatin
through upregulation of PKCa
We first assessed the sensitivity of BXPC3 cells to differ-
ent chemotherapeutic drugs. The IC50 values were 25,
100, 10, 6, 40 and 5 μg/ml for 5-FU, gemcitabine, oxali-
platin, cisplatin, CPT-11, and epirubicin, respectively
(Figure 4). We then chose cisplatin for the following
experiments. TGF-b1 significantly decreased the sensi-
tivity of BxPC3 cells to cisplatin when the cells were
pre-incubated with 5 or 10 ng/ml TGF-b1 before cispla-
tin treatment (P < 0.01, Figure 5). Furthermore, PKCa
and P-gp proteins were upregulated in a dose- and
time-dependent manner (Figure 6). In addition, TGF-b1
increased p38 phosphorylation, but not ERK1/2 phos-
phorylation (Figure 6).
To determine whether the induced PKCa activity is
responsible for the TGF-b1-induced decrease in the sen-
sitivity of BxPC3 cells to cisplatin, we treated the cells
with a selective PKCa inhibitor, Gö6976, and assessed
TGF-b1-induced drug resistance. We found that inhibi-
tion of PKCa activity could partially reverse TGF-b1-
induced drug resistance of BxPC3 cells to cisplatin
(Figure 7).
Blockade of PKCa and TbRII reversed the resistant status
of BxPC3 cells
We designed and constructed a TGF-b type II receptor
(TbRII) siRNA expression vector to knockdown TbRII
expression. We stably transfected the TbRII siRNA vec-
tor into BxPC3 cells and isolated three stable clones.
Western blotting analysis showed that TbRII expression
was significantly knocked down in clone 2 relative to
Figure 1 The effects of TGF-b1 on the cellular morphology in BxPC3 cells. Cells transfected with TGF-b1 plasmid take on a long spindle
shape with less cell-to-cell contact than the untreated group or the mock group. Cells in the latter two groups are oval or blunt shape with
close cell contact.
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subjected to a migration assay.
Figure 3 Western blotting analysis of gene expression.S t a b l y
TGF-b1-transfected BxPC3 cells were grown and treated with G418,
and total cellular protein was isolated and subjected to Western
blotting analysis. a-SMA, a mesenchymal marker, is responsible for
the enhanced cell mobility. CyclinD1 is responsible for cell growth,
while p21WAF1 is involved in cell growth arrest.
Figure 4 Resistances of BxPC3 cells to various anti-cancer
drugs. BxPC3 cells were incubated with the drugs for 48 hours.
Then cell viability was assayed by MTT. Cisplatin showed the
strongest anti-tumor ability, with a typical dose-effect curve;
gemcitabine showed almost no effect on cellular survival. BPC,
Blood peak concentration of drugs.
Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:104
http://www.jeccr.com/content/29/1/104
Page 5 of 12the other two clones (Figure 8A). We chose clone 2 for
the following experiments. The IC50 of clone 2 to gem-
citabine was 812 μg/ml, much lower than that for the
vector-only-transfected BxPC3 and the parental cells
(Figure 8B), indicating that knockdown of TbRII
increases the mortality of cancer cells and increases sen-
sitivity to gemcitabine.
Detection of differential gene expression after TGF-b1
transfection using an SSH assay
A suppressive subtracted hybridization (SSH) assay was
performed to identify differential expression of genes in
BXPC3 cells after they were stably transfected with
TGF-b1. We found a total of 33 cDNA clones after dot
hybridization, out of which 10 genes were upregulated
and 13 genes were down-regulated (Table 1). After we
BLASTed these clones using online tools, we found that
some of the genes are involved in drug resistance
(AKR1B10 and PKCa), stromal genesis (MGEA5, FN1,
APLP2, PLOD2, WDR1, and CAPZA1), and cell prolif-
eration (eEF1A1, SLC25A3, and SEC61B).
Overexpression of TGF-b1, P-gp, and membranous PKCa
in pancreatic cancer tissues
To determine the expression levels of TGF-b1, P-gp,
and PKCa in human samples in ex vivo, we immunos-
tained sections of pancreatic cancer tissues and the cor-
responding non-cancerous tissues from 42 patients. As
shown in Table 2 and Figure 9, we observed overexpres-
sion of TGF-b1, P-gp, and membranous PKCa in pan-
creatic cancer tissues. Specifically, tumor cells showed a
significantly higher rate of membranous staining for
PKCa than non-neoplastic ductal cells (p < 0.01) (Table
2 and Figure 9A). In non-neoplastic ductal cells, PKCa
stained weakly, and positive signals were mostly located
in the cytoplasm (Figure 9B). Moreover, staining for
TGF-b1 and P-gp was mainly localized in the cytoplasm
of tumor cells (Figure 9C &9D). TGF-b1 was diffusely
expressed in most tumor tissues (80.9%), but weakly
stained in normal ductal cells (19.1%). Again, P-gp
expression was found in 35 cases (83.3%) of tumor
tissues, while P-gp was weakly positive in the non-
neoplastic pancreas (11.9%)(Table 2).
Figure 5 Effects of TGF-b1 on tumor cell survival. (A) BxPC3 cells were pre-incubated with 5 and 10 ng/ml of TGF-b1 or 1% FBS as a control
for 24 h and then treated with various concentrations of cisplatin for additional 48 h. Cell viability was determined by the MTT assay. (B) IC50
values (μg/ml) of cisplatin were calculated based on the above treatment in the tumor cells. *represents significant difference of IC50 value
between group ‘1%FBS + 5 ng/ml TGF-b1’ and group ‘1%FBS’ (P = 0.03); **represents significant difference between group ‘1%FBS + 10 ng/ml
TGF-b1’ and group ‘1%FBS’ (P = 0.044).
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patients’ clinicopathological findings (Table 3) and
found that PKCa expression was not correlated with
histological type, tumor stage or nodal status. However,
w ed i df i n dt h a tt h ee x p r e s s i o nl e v e l so fb o t hT G F - b1
and P-gp are associated with poor differentiation of
tumors (p < 0.05). In addition, PKCa expression is cor-
related with expression of TGF-b1a n dP - g p( R R=
0.465 and 0.412, p < 0.01, respectively), and expression
of TGF-b1 with P-gp expression (RR = 0.759, p < 0.01)
(Table 4, 5).
Discussion
In this study, we determined the role of TGF-b1a n di t s
signaling pathway in regulating the growth and sensitiv-
ity to chemotherapeutic drugs of pancreatic cancer cells.
We found that induction of TGF-b1 expression reduced
tumor cell growth, but promoted tumor cell migration.
Furthermore, pretreatment of tumor cells with TGF-b1
induced resistance to the chemotherapeutic drug cispla-
tin in pancreatic cancer, which was mainly mediated by
PKCa and P-gp. However, inhibition of PKCa by its
i n h i b i t o rG ö 6 9 7 6o rk n o c k d o w no fT bRII by siRNA
reversed the resistance of BxPC3 cells to gemcitabine,
even in the presence of TGF-b1. Immunostaining
showed that pancreatic cancer tissues overexpress TGF-
b1 and P-gp compared to non-cancerous tissues. In
addition, TGF-b1 expression was associated with P-gp
and membranous PKCa expression in pancreatic cancer
tissues. The data from the current study demonstrate
that TGF-b1-induced drug resistance in pancreatic can-
cer cells was associated with PKCa expression. Our
findings suggest that the PKCa inhibitor Gö6976 could
be a promising sensitizer for chemotherapy in pancreatic
cancer.
Overexpression of TGF-b1 in pancreatic cancer cells,
either by gene transfection or by addition of recombi-
nant TGF-b1, enhances tumor cell resistance to cispla-
tin. There are several potential molecular mechanisms
that could be responsible for this drug resistance. For
example, Warenius et al reported that upregulated
cyclinD1 might be responsible for cis-diamminedichlor-
oplatinum (CDDP) resistance in cancer cells [20], and
Zhang et al suggested that the cell cycle inhibitor
p21
waf1 might synergize with bcl-2 to confer drug resis-
tance by inhibiting anti-cancer drug induced-apoptosis
[21]. Indeed, our study shows that a reduced S phase of
the cell cycle is associated with decreased cyclinD1 and
increased p21
waf1 expression after TGF-b1 treatment.
Furthermore, our data show that TGF-b1i n d u c e s
expression of a-SMA, a marker of the epithelial-to-
mesenchymal transition, which often results in drug
resistance in cancer cells [18,19,22-24]. In addition to
induction of a-SMA expression, we also found modula-
tion of other stroma-related molecules (such as fibro-
nectin, APLP2, and PLOD2) by TGF-b1 transfection.
These data may indicate that TGF-b1-induced effects on
the epithelial-to-mesenchymal transition contribute to
drug resistance in pancreatic cancer.
In addition, we found that PKCa is also involved in
the drug resistance of pancreatic cancer. SSH screening
revealed that PKCa is upregulated by TGF-b1v i at h e
Smad4-independent pathway. The role of PKCa in can-
cer drug resistance has been under investigation for dec-
ades [25,26]. Our data show that TGF-b1 induces PKCa
expression in a time- and dose-dependent manner, sug-
gesting that PKCa is indeed regulated by TGF-b1.
PKCa cooperates with P-gp in drug resistance by upre-
gulating or phosphorylating P-gp protein [27-30]. In line
with the increased PKCa l e v e l ,w ef o u n dt h a tP - g p
expression is also elevated. Immunohistochemical data
show higher levels of TGF-b1 and P-gp expression in
pancreatic cancer tissues th a ni nn o r m a ld u c t a lc e l l s .
O’Driscoll et al demonstrated that pancreatic cancers
expressed high levels of P-gp protein, rather than
another multidrug resistance-associated protein MRP-1
[31]. In pancreatic cancer cell lines, P-gp expression was
also shown elevated at different levels [32]. Our findings
Figure 6 The effects of TGF-b1o ne x p r e s s i o nl e v e l so fP K C a
and p38 MAPK. BxPC3 cells were treated with 0.1, 1 and 10 ng/ml
TGF-b1 for 10 min, 30 min and 24 h. Total cellular protein was
extracted and subjected to western blotting analysis to detect
expression of PKCa, phosphorylated-p38/total p38 MAPK and
phosphorylated-ERK1/2/total ERK1/2. Bx represents BxPC3 cells and
Bx/T represents the stably transfected BxPC3 cells with TGF-b1
plasmid.
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tionally related.
Although we observed no remarkable difference in
PKCa expression between cancerous and normal tissues
of the pancreas, we did observe that membranous stain-
ing of PKCa was more obvious and was significantly
correlated with P-gp expression in tumor tissues. Differ-
ent subcellular localizations of PKCa cause different
biological activities [33-36]. In mediating drug resis-
tance, PKCa translocates from the cytoplasm to the
membrane, phosphorylates the linker region of P-gp,
activates the pump (P-gp), and subsequently causes
reduction of intracellular drug accumulation. In this
respect, the membrane-associated PKCa should be con-
sidered as the functional form that coordinates with P-
gp. TGF-b1 inhibits the growth of PC3 (a prostate
cancer cell line with wild-type Smad4) by decreasing the
membrane-associated PKCa, not by altering the total
level of PKCa [37]. Another study showed that TGF-b1
suppressed PTEN expression in Smad4-null pancreatic
cancer cells by activating PKCa [38]. These data suggest
that the existence of Smad4 may repress the Smad4-
independent pathway of TGF-b1 by inhibiting functions
of several modulators (such as PKCa).
Therefore, we propose that a Smad4-independent TGF-
b1 pathway may promote the drug resistant phenotype in
pancreatic cancer through PKCa and P-gp. Studies have
shown that the MAPK and ERK pathway may be the
downstream signaling pathways activated by TGF-b1.
Several studies showed that p38 and ERK pathways
might mediate Smad4-independent TGF-b1r e s p o n s e s
[39-41]. Our data show that TGF-b1 treatment induces
Figure 7 MTT assay. (A) BxPC3 cells were grown in DMEM containing 5 μg/ml of TGF-b1 and then treated with or without Gö6976, an
inhibitor of PKCa at the indicated concentrations. After this pretreatment, the cells were further treated with cisplatin for an additional 48 h, and
the cell viability was determined via MTT assay. (B) IC50 values. * represents a significant difference in IC50 values between groups for TGF-b1( 5
ng/ml) and all other groups.
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Page 8 of 12Figure 8 Role of TbRII siRNA in BxPC3 cells. (A) Western blotting analysis of TbRII (type II receptor or TGF-b1) protein levels. BxPC3 cells were
grown and transfected with TbRII siRNA. After selection with G418, three clones were isolated and the cells from these clones underwent
protein isolation. They were subjected to Western blotting analysis with anti-TbRII antibody. Lane 1, total pool of BxPC3 cells; lane 2, mock clone
(transfected with empty plasmid, psilenser 2.1 U6); lane 3, knockdown (KD) clone 1; lane 4, KD clone 2; and lane 5, KD clone 3. (B) MTT assay.
The transfected BxPC3 cells were grown and treated with gemcitabine at the indicated doses for 2 days. The cell viability was detected by using
the MTT assay. The data show that inhibition of TbRII increases sensitivity of BxPC3 cells to gemcitabine. The IC50 value of clone 2 to
gemcitabine was the lowest, indicating that clone 2 is more sensitive to gemcitabine than the other cells (P < 0.05).
Table 1 Differentially expressed genes after stable TGF-b1 transfection
Gene designation Gene
homology
Unigene
ID
Gene function Appearance
Up-regulated genes
EEF1A1 Known Hs.439552 Protein synthesis 6
PRKCA Known Hs.349611 Protein Kinase C-a 2
Homo sapiens chromosome 17, clone RP13-63C9 Unknown KIAA1554 1
Human DNA sequence from clone RP5-827L5 on
chromosome 20
Unknown 1
AKR1B10 Known Hs.116742 Aldose reductase 1
Homo sapiens 3 BAC RP11-461M2 Unknown 1
FLJ20296 Unknown Hs.440401 Hypothetical protein 1
MGEA5 (meningioma expressed antigen 5) Known Hs.5734 hyaluronidase 1
APLP2 Known Hs.370247 Amyloid beta 1 precursor-like protein 2 1
FN1 Known Hs.203717 Fibronectin 1
Down regulated genes
CAPZA1 Known Hs.309415 Actin filament muscle 1
PLOD2 Known Hs.41270 Procollagen-lysin 2
PEG10 Unknown Hs.137476 Predicted protein 1
HNRPDL Known Hs.372673 RNA binding protein 3
KIAA1423 Unknown Hs.99145 KIAA library 1
Wdr1 Known Hs.85100 Promotion of actin degeneration 1
FTL Known Hs.433670 Ferritin 1
SEC61B Known Hs.191887 Sec61 beta subunit 1
SLC25A3 Known Hs.290404 2
KIAA0759 Unknown Hs.7285 KIAA library 1
WIPI49 Known Hs.9398 WD40 repeat protein interacting with PI
of 49kd
1
Chromosome 16, RP11-27L11 Unknown 1
Transcribed locus Unknown 1
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Page 9 of 12phosphorylation of p38 but not ERK1/2. We believe that
in absence of Smad4 (BxPC3 cells lack of Smad4 expres-
sion) TGF-b1 activates p38 but not ERK1/2 as a transient
mediator in its signaling cascades.
Indeed, we found that inhibition of PKCa or silence of
TbRII reverses the resistance of BxPC3 cells to the che-
motherapeutic drugs gemcitabine and cisplatin, suggest-
ing that the PKCa inhibitor Gö6976 is a potential
sensitizer to chemotherapy. Inhibition of PKCa function
has been shown to effectively restore the drug-sensitive
phenotype of cancer cells [42]. The PKCa inhibitor used
in this study is a small molecule that has been reported
to effectively abrogate DNA damage-induced cell cycle
arrest and induce apoptosis [43]. In addition, we found
that targeting TbRII by using siRNA did not achieve the
same effect as Gö6976; it merely helped reverse gemci-
tabine resistance to a certain extent. However, tumor
cells still remained tolerant to gemcitabine treatment.
Another study demonstrated that the blockade of TbRII
Table 2 Distribution of P-gp, TGF-b1 and PKCa
expression between pancreatic carcinomas and
corresponding non-cancer tissues
Group P-gp TGF-b1 PKCa
Membrane Plasma
Carcinoma 35 (83.3%) 34 (80.9%) 25 (59.5%) 22 (52.3%)
Non-cancer 7 (16.7%)* 8 (19.1%)* 2 (4.8%)* 35 (83.3%)*
*P < 0.01
Figure 9 Immunohistochemical analysis. Representative staining of membranous PKCa (A) in pancreatic cancer tissues, cytoplasmic PKCa (B)
in normal pancreas, P-gp (C) in pancreatic cancer tissues, and TGF-b1 (D) in pancreatic cancer tissues.
Table 3 Assocaition between TGF-b1, m-PKCa, or P-gp
expression and clinicopathological factors
Variable Number of
patients
TGF-b1 Membranous
PKCa
P-gp
+% + % +%
Differentiation
Well 7 5 71.4 3 42.9 6 85.7
Intermediate 30 28 93.3 20 66.7 27 96.7
Poor 5 1 20 2 40 2 40
LN metastasis
Positive 13 9 69.2 7 77.8 10 76.9
Negative 39 25 86.2 18 65.5 25 93.1
Neural
invasion
Positive 13 9 69.2 5 77.8 11 84.6
Negative 29 25 86.2 20 80 24 82.7
Metastatis
Positive 11 7 63.6 6 85.7 8 72.7
Negative 31 27 87.1 19 70.4 27 93.5
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Page 10 of 12could not completely shut down the pathway, which
may be because TbRI itself may be sufficient to transmit
the TGF-b1 signal [43]. All of these findings suggest
reasons why the PKCa inhibitor might be more effective
in re-sensitizing cancer cells to cisplatin than that of
TbRII silencing.
In summary, we have demonstrated that TGF-b1-
induced drug resistance in pancreatic cancer was
mediated by upregulation of both PKCa and P-gp
expression and by induction of the epithelial-to-
mesenchymal transition. The PKCa inhibitor Gő6976,
but not TbRII silencing, restores the sensitivity of pan-
creatic cancer cells to cisplatin or gemcitabine. There-
fore, our findings may cast new light on a future
application of the PKCa inhibitor as a sensitizer in che-
motherapy for pancreatic cancer.
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